Arbutus Biopharma terminated its Chief Medical Officer Karen Sims on March 25, 2025, and Chief Financial Officer David Hastings on March 27, 2025, both receiving post-termination agreements; a lawsuit against Moderna regarding patent infringement is ongoing with a trial set for September 29, 2025.